Prehypertension (PHTN) is a global major health risk that focuses individuals to double the risk of cardiovascular disease (CVD) independent of progression to hypertension. Its prevalence rate varies considerably from country to country ranging between 21.9% and 52%. Several laboratory studies shows that adiponectin suppresses certain pathophysiological processes related to endothelial dysfunction, inflammation and atherosclerosis but its association with prehypertension and risk for cardiomeabolic syndrome remain sparse. Hence the present study was undertaken to evaluate role of adiponectin as a biomarker for the early prediction of cardiometabolic syndrome in prehypertensive subjects. The present study included 75 subjects with prehypertension and 48 healthy age and sex matched controlssubjects. The mean adiponectin value of study subjects was lower than healthy control subjects. This indicates that when adiponectin level decreases the chances of having cardiometabolic syndrome increases. Thus adiponectin has an inverse or strong negative association with cardiometabolic syndrome. Therefore the study suggests that modification of lifestyle and proper medications will help to improve the level of adiponectin, thus lower the risk of CMS in prehypertensive subjects.